|RIP1 (293T cells)|
|In vitro||DMSO||52 mg/mL (200.51 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||<1 mg/mL (<1 mM)|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||38.56 mL||192.8 mL||385.61 mL|
|0.5 mM||7.71 mL||38.56 mL||77.12 mL|
|1 mM||3.86 mL||19.28 mL||38.56 mL|
|5 mM||0.77 mL||3.86 mL||7.71 mL|
*The above data is based on the productmolecular weight 259.33. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
QNZ inhibits the activation of the transcription factor NF-κB and has been used to investigate NF-κB signaling.
Lenalidomide is a derivative of thalidomide. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of the m…
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and…